ABPI comment on Operation Yellowhammer publication
The Government has published the documents relating to 'Operation Yellowhammer' with planning assumptions for a 'no-deal' Brexit.
In response, Dr Sheuli Porkess, Executive Director of Research, Medical and Innovation at ABPI said:
“Companies have been planning for the scenarios in this report for many months, including increasing stocks and planning alternative supply routes where possible - stockpiling is just part of this detailed planning.
“Government measures have supported these preparations. Companies now need the practical detail on how some of these measures, like additional freight capacity, will work in practice.”
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.